2024 | | Lower Atrial Fibrillation Risk With Sodium-Glucose Cotransporter 2 Inhibitors Than With Dipeptidyl Peptidase-4 Inhibitors in Individuals With Type 2 Diabetes: A Nationwide Cohort Study | 김대중, 하경화 |
2024 | | Imeglimin attenuates NLRP3 inflammasome activation by restoring mitochondrial functions in macrophages | 김대중, 김혜진, 이관우, 전자영, 한승진 |
2024 | | Effectiveness and safety of sodium–glucose cotransporter 2 inhibitors in Asian populations | 김대중, 하경화 |
2023 | | 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association | 김대중, 김혜진 |
2023 | | Amphiregulin Induces iNOS and COX-2 Expression through NF- κ B and MAPK Signaling in Hepatic Inflammation | 강엽, 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
2023 | | Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia | 김대중, 하경화 |
2023 | | Long-term Effectiveness of the National Diabetes Quality Assessment Program in South Korea | 김대중, 하경화 |
2023 | | Diet quality partially mediates the association between ultraprocessed food consumption and adiposity indicators | 김대중, 하경화 |
2023 | | Associations of updated cardiovascular health metrics, including sleep health, with incident diabetes and cardiovascular events in older adults with prediabetes: A nationwide population-based cohort study | 김대중, 하경화, 한승진 |
2023 | | Ultra-Processed Food Consumption and Obesity in Korean Adults | 김대중, 하경화 |
2023 | | Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study | 김대중 |
2023 | | Impact of Post-Transplant Diabetes Mellitus on Survival and Cardiovascular Events in Kidney Transplant Recipients | 김대중, 김혜진, 박범희, 이관우, 전자영, 한승진 |
2023 | | Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study | 김대중, 하경화 |
2023 | | Diabetes screening in South Korea: a new estimate of the number needed to screen to detect diabetes | 김대중, 하경화 |
2023 | | Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study | 김대중, 하경화 |
2022 | | Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease | 강엽, 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
2022 | | Characteristics and Clinical Course of Diabetes of the Exocrine Pancreas: A Nationwide Population-Based Cohort Study | 김대중, 김혜진, 이관우, 이나미, 전자영, 한승진 |
2022 | | Psychometric Properties of the Korean Version of the Perceived Therapeutic Efficacy Scale for Physical Activity in Adults With Type 2 Diabetes | 김대중, 김춘자 |
2022 | | Association of prediabetes with death and diabetic complications in older adults: The pros and cons of active screening for prediabetes | 김대중, 하경화 |
2022 | | Maintaining Physical Activity Is Associated with Reduced Major Adverse Cardiovascular Events in People Newly Diagnosed with Diabetes | 김대중, 하경화 |